{"protocolSection":{"identificationModule":{"nctId":"NCT00448214","orgStudyIdInfo":{"id":"150-CL-030"},"organization":{"fullName":"Astellas Pharma Inc","class":"INDUSTRY"},"briefTitle":"Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation","officialTitle":"Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation - A Double Blind, Parallel, Dose-finding Study in Comparison With Open Label Warfarin"},"statusModule":{"statusVerifiedDate":"2011-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-03"},"primaryCompletionDateStruct":{"date":"2008-10","type":"ACTUAL"},"completionDateStruct":{"date":"2008-10","type":"ACTUAL"},"studyFirstSubmitDate":"2007-03-15","studyFirstSubmitQcDate":"2007-03-15","studyFirstPostDateStruct":{"date":"2007-03-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-12-15","lastUpdatePostDateStruct":{"date":"2011-12-19","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Astellas Pharma Inc","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"To evaluate the safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation (NVAF)and to obtain information on pharmacokinetics and pharmacodynamics (anti-thrombotic potential) in the target population"},"conditionsModule":{"conditions":["Atrial Fibrillation"],"keywords":["Factor Xa inhibitor","Atrial fibrillation","Stroke","Ischemic attack","thromboembolism","Prevention and control"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":448,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"Low dose","interventionNames":["Drug: YM150"]},{"label":"2","type":"EXPERIMENTAL","description":"Middle dose","interventionNames":["Drug: YM150"]},{"label":"3","type":"EXPERIMENTAL","description":"High dose","interventionNames":["Drug: YM150"]},{"label":"4","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: warfarin"]}],"interventions":[{"type":"DRUG","name":"YM150","description":"Oral","armGroupLabels":["1","2","3"]},{"type":"DRUG","name":"warfarin","description":"Oral","armGroupLabels":["4"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"All clinically relevant bleeds during the treatment period rated as \"major\" or \"clinically relevant non-major(CRNM)\"","timeFrame":"16 Weeks"}],"secondaryOutcomes":[{"measure":"Incidence of symptomatic stroke","timeFrame":"16 Weeks"},{"measure":"Incidence of transient ischemic attack (TIA)","timeFrame":"16 Weeks"},{"measure":"Incidence of systemic thromboembolic event","timeFrame":"16 Weeks"},{"measure":"Incidence of the bleeding rates","timeFrame":"16 Weeks"},{"measure":"Other safety assessments","timeFrame":"16 Weeks"},{"measure":"PK, PD variables","timeFrame":"16 Weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nSubjects are eligible for the study if all of the following apply:\n\n* Subject has paroxysmal permanent or persistent NVAF\n* Subject has INR of 2.0 or below and an aPTT â‰¤ 1.5 times the upper limit of normal at the baseline visit.\n* Legal minimum age requirement (country-specific).\n* Written informed consent has been obtained.\n\nExclusion Criteria:\n\n* History of heart valve disorders\n* History of rheumatic fever.\n* History of stroke and/or systemic embolism (including TIA).\n* History of Acute Coronary Syndrome (ACS).\n* Indication for warfarin other than NVAF.\n* Known hemorrhagic disorder and/or coagulation disorder.\n* Active bleeding or any condition associated with increased risk of bleeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Central Contact","affiliation":"Astellas Pharma Inc","role":"STUDY_CHAIR"}],"locations":[{"city":"Launceston","country":"Australia","geoPoint":{"lat":-41.43876,"lon":147.13467}},{"city":"Pok Fu Lam","country":"Hong Kong"},{"city":"Sha Tin","country":"Hong Kong","geoPoint":{"lat":22.38333,"lon":114.18333}},{"city":"Hokkaido","country":"Japan","geoPoint":{"lat":43.41104,"lon":142.88878}},{"city":"Kansai","country":"Japan"},{"city":"Kanto","country":"Japan"},{"city":"Kyusyu","country":"Japan"},{"city":"Shikoku","country":"Japan"},{"city":"Tohoku","country":"Japan","geoPoint":{"lat":35.81882,"lon":139.57138}},{"city":"Seoul","country":"Korea, Republic of","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"kuala Lumpur","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"city":"Hastings","country":"New Zealand","geoPoint":{"lat":-39.6381,"lon":176.84918}},{"city":"Singapore","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"city":"Bloemfontein","country":"South Africa","geoPoint":{"lat":-29.12107,"lon":26.214}},{"city":"Taipei","country":"Taiwan","geoPoint":{"lat":25.04776,"lon":121.53185}},{"city":"Bangkok","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"city":"Chiang Mai","country":"Thailand","geoPoint":{"lat":18.79038,"lon":98.98468}},{"city":"Nakhon Ratchasima","country":"Thailand","geoPoint":{"lat":14.97066,"lon":102.10196}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M16372","name":"Thromboembolism","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014859","term":"Warfarin"}],"ancestors":[{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M17292","name":"Warfarin","asFound":"Third","relevance":"HIGH"},{"id":"M227242","name":"Darexaban","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}